The potential of liposomal cancer vaccines

G protein-coupled receptors (GPCRs), one of the largest families of membrane proteins, are responsive to a diverse set of physiological endogenous ligands including hormones and neurotransmitters.

Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.

Promotores: W. Jiskoot, F. Ossendorp

Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.

This thesis focuses on using liposomes in two different treatment strategies; vaccination (or immunotherapy) and delivery of a small molecule, and in two different disease models; cancer and atherosclerosis.

Winning a prestigious award for PhD researchers, even before you have your doctorate: that's what Yascha van den Berg managed to do with his research proposal on alternatively spliced tissue factor, a protein that may be involved in tumour growth. Van den Berg: ‘It all started as a Friday afternoon…

We already know a lot about genetics and the risk of breast cancer. But much still needs to be done in breast cancer genetics to improve the prognosis and make sure women at high risk aren’t missed. This is what Professor by Special Appointment Marjanka Schmidt will say in her inaugural lecture on 4…

Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…

Leiden biophysicist Stefano Coppola has received the prestigious AXA Research Fund postdoctoral fellowship. With this grant he can work for two years on a project to research the role of mechanical factors in the development of pancreatic cancer.

Leiden PhD student Xuequan Zhou has designed a new promising molecule that efficiently kills cancer cells, but does not harm healthy tissue. The trick: the drug is only active when irradiated with light. Zhou’s new compound does this extra efficiently by cleverly self-organising into nanoparticles.…

Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…

Leiden University Medical Center (LUMC) has spent the past five years coordinating an international study of genetic mutations and breast cancer risks. The results will make it easier to determine which genes increase the risk of breast cancer and to what extent. The researchers published their results…

Ariane Briegel wants to use bacteria to detect cancer at an early stage. Together with postdoc Alise Muok, she is developing a method to quickly and cheaply test the urine of patients for the presence of suspicious molecules. They receive a grant of approximately 150,000 euros from the Dutch Cancer…

Sebastian Pomplun manages to reach proteins with drugs even where this was thought impossible. That is why he and his research group have been allowed to join Oncode Institute. With nine others, he had been selected from 72 applicants to contribute to Oncode Institute's mission: to accelerate breakthroughs…

With a Vici grant of 1.5 million euros, Professor of Mathematical biology Roeland Merks will look for ways to fix messy and leaky blood vessels in tumours. His research combines mathematical simulations and lab experiments in a unique way.

Modified viruses can both kill cancer cells and activate the immune system. This is what an LUMC team discovered while researching a new prostate cancer therapy.

A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by ISA Pharmaceuticals B.V. (a Leiden-based biotechnology company) and the Leiden University Medical Center (LUMC) shows that this vaccine produces a more robust response…

Chemist Gerjan de Bruin has designed a method of slowing down the degradation process of proteins in cells. This may contribute to new cancer medicines with fewer side-effects. PhD defence on 1 June.

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

The research within the Division of Cell Systems and Drug Safety, headed by Prof. Bob van de Water, is focused on novel therapeutic modalities and novel concepts in early drug discovery, in order to develop more effective and safer therapeutic strategies. We generate advanced cell and computational…

Leiden chemists, together with colleagues at the University of York (UK) and Technion (Israel) have discovered a small, sugar-like molecule that maintains the integrity of tissue around a tumour during cancer. This molecule prevents tumour cells from spreading from the primary cancer site to colonise…

Cell biologist Erik Danen has been awarderd a grant of half a million euros to study how tumor cells spread throughout the body en develop drug resistance. This was announced mid-August by the Dutch Cancer Society Fund (KWF).

Researchers of the Leiden University Medical Centre (LUMC) and the Leiden Institute of Chemistry have made an important discovery about the commonly used anti-cancer drug doxorubicin. They have found a way to reduce its side effects without sacrificing the effectiveness of the medication. This is encouraging…

Biological chemist Nathaniel Martin and his team received an NWO grant to examine how blocking a specific enzyme in our body, NNMT, could be helpful in the treatment of some cancers. Trials with mice have been promising, and together with the Netherlands Cancer Institute, Martin wants to take the next…

A cancer pill, preferably without severe side effects, is something we’d all welcome. Is it a matter of time before such a pill is a reality? We put this question to three Leiden researchers and asked how they themselves are contributing to new cancer treatments.

Marta Fiocco, professor at the Mathematical Institute, has received a grant for predicting survival outcome and improving the balance between prognosis and quality of life for soft tissue sarcoma patients (Personalised Sarcoma Care).

A new technique using fluorescent imaging to track the actions of enzymes might aid drug design for new anti-cancer, inflammation and kidney disease treatments. Researchers at the University of York and Leiden University have published these findings in Nature Chemical Biology.

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.

The European Commission has granted budget for the project INFORM (Introduction of the data protection reform to the judicial system). Dr. Bart Custers, associate professor and head of research at eLaw, the Center for Law and Digital Technologies, has written the proposal with nine partner organizations…

An international group of scientists has discovered that certain cells of our immune system – the so-called T cells – communicate with each other and work together as a team. To fight an infection they stimulate each other’s growth, but at the same time, they inhibit each other when there is a surplus…

This year’s theme of the Cyber Summit is: “Using Technology Responsible”. The Cyber Summit will take place in Banff, Canada on October 26th-28th. Dr. Bart Custers, associate professor and head of research at eLaw, the Center for Law and Digital Technologies, is invited to give a presentation on privacy…

The European Commission has granted budget for the project e-SIDES (ethical and societal implications of data science). Dr. Bart Custers, associate professor and head of research at eLaw, the Center for Law and Digital Technologies, has written the proposal with two partner organizations within the…

When you think of physics, do you think only of complicated formulas? You’re not the only one. Therefore, every year, the Leiden Insitute of Physics organises the LION Image Award to show another side of physics: beautiful images about intriguing science. The winner of the 2022 photo competition captured…

Leiden researchers have developed a groundbreaking model to advance cancer immunotherapy. Using a 3D printer, they create mini-tumors within an environment that closely mimics human tissue. They have also developed a method to monitor real-time interactions of these mini-tumours with immune cells during…

On 11 November Professor of Gastroenterology and Hepatology, Monique van Leerdam will deliver her inaugural lecture entitled, ‘Aiming for Prevention’. Van Leerdam, who specialises in hereditary tumours, was appointed professor in July 2020. In her inaugural lecture she will discuss the importance of…

Patients with incurable cancer want their oncologist to be clear but to show empathy too. They find hard and vague communication harmful. These are the results of a study by psychologists from Leiden that has been published in the American journal Cancer.

The advanced insights obtained for the CNS PBPK model development are currently used to develop advanced mathematical models for drug distribution prediction in other body tissues protected by barriers, such as the gut. The gut PBPK model will be linked to drug effects for treatment of colon cancer.

This project is funded by the Dutch Cancer Society. The project will be part of an ongoing research line aimed at identifying mechanisms of cancer therapy resistance and metastasis. In this project, it will be investigated how the Grainyhead family of transcription factors controls therapy response…

Liposomes hold great promise for peptide-based personalized cancer vaccination, especially when administered intradermally. However, current liposome preparation methods are very time consuming (resulting in long development times per formulation), whereas personalized cancer vaccination requires very…

PhD defence

In 2013, Sylvestre Bonnet received an ERC Starting Grant to kill cancer with molecules that can be activated by light. Two postdocs and three PhD students later, the end approaches of his so far successful project.

The European Cooperation in Science and Technology (COST) has awarded a network grant for the project GoodBrother. On behalf of Leiden University, Bart Custers, professor of Law & Data Science and director of eLaw, the Center for Law and Digital Technologies, contributed to writing this proposal.

Death in all types of melanomas is generally caused by metastasis. Uveal melanoma (UM) is the most common intraocular melanoma, there are currently no (patient-derived) animal models that faithfully recapitulate metastatic dissemination of UM.

Researchers from the Leiden University Medical Center (LUMC) have developed an AI model that accurately predicts the risk of endometrial cancer recurrence.

Intrigued by the way cells autonomously regulate their fate, we strive to understand and visualize cellular processes as the basis of Cell Signaling.

We are interested in understanding the mechanics of soft materials, of which biological materials are prominent examples.

When the immune system attacks cancer, the tumour modifies itself to escape the immune reaction. Researchers at LUMC published on this subject in Nature on 28 June.